2020
IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis
Shin MS, Kim D, Yim K, Park HJ, You S, Dong X, Koumpouras F, Shaw AC, Fan R, Krishnaswamy S, Kang I. IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis. Cellular Immunology 2020, 355: 104155. PMID: 32619811, PMCID: PMC7415611, DOI: 10.1016/j.cellimm.2020.104155.Peer-Reviewed Original ResearchConceptsSingle-cell RNA-seqHuman effector memory CD8Effector memory CD8T cellsIL-7RαMemory CD8Gene regulationTranscription factorsRNA-seqPossible biological significanceDownstream eventsEM CD8Expression patternsExpressional relationshipDifferential expressionCytokine receptorsComprehensive landscapeHigh-dimensional cytometryBiological significanceIL-7 receptor alphaKey moleculesIL-7 receptor alpha chainReceptor alpha chainBiological implicationsHeterogeneous cell subsets
2015
Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus
Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology 2015, 67: 1848-1857. PMID: 25777546, PMCID: PMC4732716, DOI: 10.1002/art.39108.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAntibodies, Anti-IdiotypicAntigensCarrier ProteinsCholecalciferolCytoskeletal ProteinsDietary SupplementsDNADose-Response Relationship, DrugDouble-Blind MethodFemaleGene Expression RegulationHumansLupus Erythematosus, SystemicMaleMicroarray AnalysisMiddle AgedMyxovirus Resistance ProteinsProspective StudiesRNA-Binding ProteinsVitamin DConceptsPercentage of patientsVitamin D3Vitamin DIFN signatureTreatment groupsSLE patientsInterferon signatureSystemic lupus erythematosus seraDNA antibody levelsVitamin D repletionPlacebo-controlled trialVitamin D deficientVitamin D supplementationVitamin D3 supplementationSubset of patientsSystemic lupus erythematosusD supplementationD deficientD3 supplementationDisease activityImmunologic outcomesInactive diseaseAdverse eventsBaseline characteristicsLupus erythematosus